Northern Trust Corp Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Northern Trust Corp raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 204,345 shares of the specialty pharmaceutical company’s stock after purchasing an additional 16,820 shares during the period. Northern Trust Corp owned approximately 0.97% of ANI Pharmaceuticals worth $11,296,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Aquatic Capital Management LLC boosted its stake in ANI Pharmaceuticals by 149.6% during the 4th quarter. Aquatic Capital Management LLC now owns 6,740 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 4,040 shares during the last quarter. Oberweis Asset Management Inc. lifted its holdings in shares of ANI Pharmaceuticals by 50.8% during the 4th quarter. Oberweis Asset Management Inc. now owns 65,600 shares of the specialty pharmaceutical company’s stock valued at $3,626,000 after buying an additional 22,100 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in ANI Pharmaceuticals by 20.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,288 shares of the specialty pharmaceutical company’s stock worth $403,000 after purchasing an additional 1,220 shares during the period. Stifel Financial Corp raised its holdings in ANI Pharmaceuticals by 20.4% in the 4th quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock worth $466,000 after purchasing an additional 1,425 shares during the period. Finally, MetLife Investment Management LLC increased its stake in ANI Pharmaceuticals by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 675 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Ori Gutwerg sold 881 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares of the company’s stock, valued at $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This trade represents a 0.49% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,681 shares of company stock valued at $468,698. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $59.99 on Friday. The company has a 50 day moving average price of $66.91 and a 200-day moving average price of $60.75. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00. The company has a market capitalization of $1.31 billion, a PE ratio of -109.07 and a beta of 0.56.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million during the quarter, compared to the consensus estimate of $179.75 million. During the same quarter in the previous year, the firm posted $0.82 earnings per share. The company’s revenue was up 43.4% on a year-over-year basis. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of a number of research analyst reports. StockNews.com lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Truist Financial lifted their price target on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research report on Monday, April 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.